Replies to post #18073 on Cytogenix (fka CYGX)

[Paulness]

holycow I reread dutton's report on CYGX it mentions acquisitions, do they know something we don't, Hmmmmmmmm.


CytoGenix Inc. Speculative Buy Rating Maintained; Benefiting from Acquisitions and Careful Management
By: William R. Prather, R.Ph., M.D.
April 01, 2005. CytoGenix Inc. (OTCBB: CYGX) has developed a core technology platform that enables the control of gene expression and the manufacture of synthetic DNA plasmids for therapeutic uses. CytoGenix’s system can prevent the production of virtually any protein so long as the gene sequence is known. The Company’s technological platform has the potential for the development of therapeutic products that could compete with small molecules and proteins that are applicable to a broad range of diseases. We are reiterating our Speculative Buy rating and assigning a price target of $0.90.